Filing Details

Accession Number:
0001209191-23-002433
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-01-06 17:39:56
Reporting Period:
2023-01-04
Accepted Time:
2023-01-06 17:39:56
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1652130 Intellia Therapeutics Inc. NTLA In Vitro & In Vivo Diagnostic Substances (2835) 364785571
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1777421 Laura Sepp-Lorenzino C/O Intellia Therapeutics, Inc.
40 Erie Street; Suite 130
Cambridge MA 02139
Evp, Chief Scientific Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2023-01-04 2,508 $37.21 19,959 No 4 S Direct
Common Stock Disposition 2023-01-05 1,641 $38.22 18,318 No 4 S Direct
Common Stock Disposition 2023-01-05 689 $39.10 17,629 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. Shares sold in sell-to-cover transaction in order to satisfy withholding taxes to be paid upon the vesting of RSUs on January 1, 2023.
  2. The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.80 to $38.78, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 5, 2023 at each separate price.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.98 to $39.30, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 5, 2023 at each separate price.